Garson Chan1, Liang G Qu2,3, Johan Gani2,4. 1. Division of Urology, Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada. 2. Department of Urology, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia. 3. Young Urology Researchers Organisation (YURO), Australia. 4. Department of Urology, University of Melbourne, Western Health, Footscray, Victoria, Australia.
Abstract
INTRODUCTION: This study identified associations between lower urinary tract pathology confirmed on urodynamic testing, baseline characteristics, and symptoms for adults with nocturia. Nocturia frequency was examined for predictors. METHODS: This retrospective study from 2012-2019 analyzed adult patients with nocturia (waking to void ≥2x/night) referred for urodynamic testing (UDS). Data on baseline characteristics, symptoms, UDS parameters, and lower urinary tract pathology were recorded. Males and females were analyzed separately, and univariable analyses were conducted, stratified by lower urinary tract pathology. Multivariable regression models were fit. Nocturia frequency was analyzed for associations with clinical parameters. RESULTS: Altogether, 372 patients were included (159 men and 213 women). More men had detrusor overactivity (DO) (p<0.001) and bladder outlet obstruction (BOO) (p<0.001). DO was associated with storage symptoms (odds ratio [OR] 5.19, p<0.001), in addition to older age (p=0.009) and being male (p<0.001). Detrusor under-activity (DU) was associated with voiding symptoms (OR 1.92, p=0.004), older age (p<0.001), and being female (p=0.018). BOO was associated voiding symptoms (OR 2.09, p=0.023), younger age (p=0.018), and being male (p<0.001). The quantity of lower urinary tract symptoms was associated with DU and DO. Nocturia frequency was not associated with baseline variables or underlying pathologies. A substantial number of patients were diagnosed with DU alone (n=69, 18.7%) or associated with other diagnoses (n=108, 29.3%). CONCLUSIONS: Careful assessment of risk factors and symptoms may help identify underlying lower urinary tract pathology for adults with nocturia. DU is found in a significant proportion of patients with nocturia, a previously under-reported result.
INTRODUCTION: This study identified associations between lower urinary tract pathology confirmed on urodynamic testing, baseline characteristics, and symptoms for adults with nocturia. Nocturia frequency was examined for predictors. METHODS: This retrospective study from 2012-2019 analyzed adult patients with nocturia (waking to void ≥2x/night) referred for urodynamic testing (UDS). Data on baseline characteristics, symptoms, UDS parameters, and lower urinary tract pathology were recorded. Males and females were analyzed separately, and univariable analyses were conducted, stratified by lower urinary tract pathology. Multivariable regression models were fit. Nocturia frequency was analyzed for associations with clinical parameters. RESULTS: Altogether, 372 patients were included (159 men and 213 women). More men had detrusor overactivity (DO) (p<0.001) and bladder outlet obstruction (BOO) (p<0.001). DO was associated with storage symptoms (odds ratio [OR] 5.19, p<0.001), in addition to older age (p=0.009) and being male (p<0.001). Detrusor under-activity (DU) was associated with voiding symptoms (OR 1.92, p=0.004), older age (p<0.001), and being female (p=0.018). BOO was associated voiding symptoms (OR 2.09, p=0.023), younger age (p=0.018), and being male (p<0.001). The quantity of lower urinary tract symptoms was associated with DU and DO. Nocturia frequency was not associated with baseline variables or underlying pathologies. A substantial number of patients were diagnosed with DU alone (n=69, 18.7%) or associated with other diagnoses (n=108, 29.3%). CONCLUSIONS: Careful assessment of risk factors and symptoms may help identify underlying lower urinary tract pathology for adults with nocturia. DU is found in a significant proportion of patients with nocturia, a previously under-reported result.
Authors: Hashim Hashim; Marco H Blanker; Marcus J Drake; Jens Christian Djurhuus; Jane Meijlink; Vikky Morris; Peter Petros; Jian Guo Wen; Alan Wein Journal: Neurourol Urodyn Date: 2019-01-15 Impact factor: 2.696
Authors: Thomas F Monaghan; Raymond Khargi; Connelly D Miller; Christina W Agudelo; Matthew J Bruha; Lauren E Fink; Jason M Lazar; Karel Everaert; Jeffrey P Weiss Journal: Neurourol Urodyn Date: 2020-10-14 Impact factor: 2.696
Authors: Julian Azuero; Jessica Santander; Carlos Gustavo Trujillo; Juan Ignacio Caicedo; Laura Zuluaga; Ana María Becerra; Fabián Daza; Martin Rondón; Mauricio Plata Journal: Neurourol Urodyn Date: 2021-02-07 Impact factor: 2.696
Authors: Hannah T Ryles; Stephanie A Sansone; Pamela J Levin; Uduak U Andy; Heidi S Harvie; Lily A Arya Journal: Female Pelvic Med Reconstr Surg Date: 2021-09-01 Impact factor: 1.913
Authors: Siri Drangsholt; Benoit Peyronnet; Maria Arcila-Ruiz; Rachael D Sussman; Ricardo Palmerola; Dominique R Pape; Nirit Rosenblum; Victor W Nitti; Benjamin M Brucker Journal: Arab J Urol Date: 2019-04-18